ClinicalTrials.gg
CompletedNCT06439381Updated Aug 13, 2026

Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps

A Phase 2 interventional study of 300mg/600mg of TQH2722 injection in Chronic Rhinosinusitis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 27 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Rhinosinusitis with a site in China — 18 open to participants now, 25 under way, 7 of them phase 3. Rhinosinusitis · China.

Enrollment
18th of 36
119 · median 117
Started
2024
with 5 others
Phase 2
12 of 40
4 open now
Registered
16th of 40
by date

Among the 40 studies in Rhinosinusitis with a site in China, this one is the 18th largest by enrollment of the 36 interventional ones that give a count, is one of 6 that started in 2024, is one of 12 in phase 2, and was the 16th registered.

Rhinosinusitis

251 studies on the registry are indexed under Rhinosinusitis; 69 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

18 of the 40 studies in Rhinosinusitis with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 33 Rhinosinusitis studies recruiting now, 14 (42%) set no upper age limit and 13 (39%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Rhinosinusitis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, continuing, Phase II expansion trial to evaluate the safety, efficacy, and immunogenicity of two doses of TQH2722 in the long-term treatment of severe chronic sinusitis with or without nasal polyps.

03

Conditions studied

  • Chronic Rhinosinusitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Inclusion Criteria of Part A

    • Sign before the test to fully understand the purpose, process and possible adverse reactions of the test;
    • Age 18-75 years old (including the threshold), male or female;
    • Enroll in the clinical study of TQH2722 for chronic sinusitis with or without nasal polyps (study number TQH2722-II-02) and meet the following criteria "a" or "b" :

      1. Subjects completed prescribed treatment as required and completed Part A end of study (EOS) visit;
      2. The subjects withdrew early due to poor compliance or other objective reasons other than TQH2722-related AE, and completed the early exit interview according to the plan, and the influencing factors that led to the subjects' early termination of the main study treatment have disappeared/no longer affected the subjects' participation in the continuation study as assessed by the investigators and sponsors.

    Note: If protocol window period requirements are met, examination results from subject's main study EOS/ early exit visit may be used as screening/baseline examination for this study.

    • Subjects had used a more stable dose of nasal (INCS) for more than 4 weeks prior to screening (for subjects who had used other INCS prior to screening than intranasal Mometasone furoate nasal spray (MFNS), subjects were willing to switch to MFNS during the study);
    • Subjects agree not to have a family plan for 6 months from the date of signing the informed consent to the last dose, and must use effective non-drug with their sexual partners of childbearing age.
  2. Inclusion Criteria of Part B

    • Sign informed consent before the test to fully understand the purpose, process and possible adverse reactions of the test;
    • Age 18-75 years old (including the threshold), male or female;
    • Enroll in the clinical study of TQH2722 for chronic sinusitis with or without nasal polyps (study number TQH2722-II-02) and meet the following criteria "a" or "b" :

      1. Subjects completed prescribed treatment as required and completed Part B EOS visit;
      2. The subjects withdrew early due to poor compliance or other objective reasons other than TQH2722-related AE, and completed the early exit interview according to the plan, and the influencing factors that led to the subjects' early termination of the main study treatment have disappeared/no longer affected the subjects' participation in the continuation study as assessed by the investigators and sponsors.

Note: If protocol window period requirements are met, examination results from subject's main study EOS/ early exit visit may be used as screening/baseline examination for this study.

  • Subjects had used a more stable dose of nasal glucocorticoids (INCS) for more than 4 weeks prior to screening (for subjects who had used other INCS prior to screening than intranasal Mometasone furoate nasal spray (MFNS), subjects were willing to switch to MFNS during the study);
  • Subjects agree not to have a family plan for 6 months from the date of signing the informed consent to the last dose, and must use effective non-drug contraception with their sexual partners of childbearing age.

Exclusion Criteria:

  • In the main study (TQH2722-II-02), a TQH2722-related SAE occurred or TQH2722-related AE led to the discontinuation of TQH2722 therapy, and after discussion between the investigator and sponsor, the subject was deemed unsuitable for continuation of TQH2722 therapy.
  • The subjects had poor compliance in the main study, and the researchers judged that they could not complete the continuing study.
  • During the main study (TQH2722-II-02), any severe progression or poorly controlled concomitant disease (such as asthma exacerbation requiring adjustment of background medication) is identified and the subject is deemed unfit to participate by the principal investigator;
  • Any of the following laboratory test values are abnormal during the screening period:

    1. (ALT) or aspartate aminotransferase (AST) >2.5 (ULN);
    2. Total > 2 x ULN (except indirect bilirubin elevation secondary to Gilbert syndrome);
    3. Creatinine > 1.5×ULN;
  • Any medical condition, including but not limited to cardiovascular, gastrointestinal, liver, kidney, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major limb disorders, that the investigator believes is unstable and may affect the patient's safety throughout the study period, or affect the study results or their interpretation, or interfere with the patient's ability to complete the entire study process.For example, but not limited to: ischemic heart disease, left ventricular failure, arrhythmia, uncontrolled hypertension, uncontrolled hyperglycemia, cerebrovascular disease, etc.;
  • Patients with active diseases (including, but not limited to, Hashimoto thyroiditis, Graves' disease, inflammatory bowel disease, primary biliary cholangitis, systemic lupus erythematosus, multiple sclerosis and other neuroinflammatory diseases, psoriasis vulgaris, rheumatoid arthritis);
  • Known or suspected individuals, including but not limited to a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pulmonary cyst disease, aspergillosis), even if the infection has resolved;
  • Subjects with active malignant tumors or a history of malignant tumors:Patients with basal cell carcinoma, skin localized squamous cell carcinoma, or cervical carcinoma in situ who had completed curative treatment for at least 12 months prior to visit 1 could be enrolled in this study; patients with other could be enrolled if they had completed curative treatment for at least 5 years prior to visit 1;
  • A history of active pulmonary tuberculosis within 12 months prior to screening;
  • Active hepatitis was present at the screening stage, either surface antigen (HBsAg) positive, hepatitis B core antibody (HBcAb) positive and Hepatitis B Virus-DNA positive, or Virus (HCV) antibody positive and HCV-RNA positive; or (Anti-HIV) positive, or treponema pallidum antibody (Anti-TP) positive (if the treponema pallidum serological test is positive, then further non-treponema pallidum serological test is performed, the latter is negative and the investigator determines that patients who have been infected with syphilis in the past but have been cured are eligible for inclusion);
  • Diagnosis of helminthic infection within 6 months prior to the screening period, failure to receive standard treatment or failure to respond to standard treatment;
  • Subjects who received the following treatments:

    1. Had sinus surgery or nasal sinus surgery within 6 months prior to screening (visit 1).
    2. Received monoclonal antibody therapy within 8 weeks or 5 half-lives prior to screening (whichever is longer);
    3. Received immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporine, interferon gamma, azathioprine, methotrexate, mycophenolate and tacrolimus) within 8 weeks or 5 half-lives prior to screening, whichever is longer;
    4. Use of other non-biological agents within 8 weeks or 5 half-lives (whichever is longer) prior to screening;
    5. Intravenous immunoglobulin (IVIG) therapy and/or plasma exchange within 30 days prior to screening visit (Visit 1);
    6. Subjects treated with leukotriene antagonists/modulators prior to screening (subjects treated with stable doses of leukotriene modulators for ≥30 days prior to screening can be enrolled);
    7. Start allergen immunotherapy within 3 months prior to screening, or plan to start such therapy during the study period or plan to change the therapeutic dose during the study period;
    8. Have received within 4 weeks prior to screening or plan to receive live attenuated vaccine during the study period;
    9. Chronic active or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasites, antivirals, or antifungals during the 4 weeks prior to screening, or a viral disease that may not have received antiviral treatment during the 4 weeks prior to screening;(Screening visits can be performed after the patient recovers from infection, but the systemic antibiotic needs to be greater than 2 weeks).
  • Patients with asthma should be excluded if: a. (FEV1) ≤ 50% of the expected normal value, or b.Acute exacerbation of asthma within 90 days prior to screening requiring hospitalization (>24 hours), or c.Are using a daily dose of fluticasone or equivalent inhaled glucocorticoids (ICS) greater than 1000mcg;
  • Subjects with asthma were initiated with inhaled corticosteroids within 4 weeks prior to the screening/induction period (for subjects who could receive a stable dose for at least 4 weeks prior to screening and whose assessed dose could be maintained throughout the study period, inhaled corticosteroids could be fluticasone propionate at a dose ≤1000μg or equivalent doses of other inhaled corticosteroids).
  • Subjects have concomitant medical conditions that prevent them from completing the screening period assessment or evaluating the primary efficacy endpoint, such as:

    1. A deviated nasal septum leads to obstruction of at least one nostril
    2. Persistent drug rhinitis;
    3. The diagnosis was eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), granulomatous polyvasculitis (Wegener's granuloma), Young's syndrome, Kartagener syndrome or other ciliary dyskinesia syndrome, cystic fibrosis;
    4. Suspected or confirmed fungal rhinosinusitis on imaging;
  • Subjects with nasal malignancies and benign tumors (e.g., papilloma, hemangioma, etc.);
  • Subjects who are unable to use MFNS or are allergic or intolerant to Mometasone furoate nasal spray;
  • Subjects with a history of systemic allergy to any biological agent (except local injection site reactions);
  • Pregnant or lactating women;
  • Alcohol, drug and known drug dependence;
  • The subjects had poor compliance in the study and could not complete the study as judged by the researcher;
  • Any medical or psychiatric condition that, in the judgment of the investigator or sponsor medical reviewer, puts the subject at risk, interferes with participation in the study, or interferes with the interpretation of the study results.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    300mg/600mg of TQH2722 injection in Part A or B

    For Part A or Part B, 300mg/600mg of TQH2722 injection was administered every 2 weeks until week 22, combined with Mometasone furoate nasal spray of 100-200μg/ day until week 32.

    Drug: 300mg/600mg of TQH2722 injection

Interventions

  • Drug300mg/600mg of TQH2722 injection

    TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events (TEAE)

    Frequency of treatment emergent adverse events (TEAE) occurring during treatment.

    Time frame: Up to 32 weeks

Secondary outcomes

  1. Serious adverse events (SAEs)

    The frequency of serious adverse events (SAEs) that occurred during treatment in subjects with chronic sinusitis with nasal polyps (CRSwNP) or chronic sinusitis without nasal polyps (CRSsNP).

    Time frame: Up to 32 weeks

  2. Abnormal laboratory test indicators

    Abnormal laboratory test indicators during treatment in subjects with chronic sinusitis with nasal polyps (CRSwNP) or chronic sinusitis without nasal polyps (CRSsNP).

    Time frame: Up to 32 weeks

  3. Changes in Lund Mackay score assessed by CT from baseline

    Change in Lund Mackay score assessed by CT from baseline. The total score is 0-24 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 24 weeks

  4. Changes in the University of Pennsylvania Smell Identification Test (UPSIT)

    The change in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline (main study TQH2722-II-02 and baseline in this study, respectively) at each evaluation time point.

    Time frame: Up to 32 weeks

  5. Changes in Nasal Total Symptom Score from baseline

    Changes in subjects' Nasal Total Symptom Score from baseline. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 32 weeks

  6. Changes in the sinusitis Visual Analogue Scale (VAS) score from baseline

    Changes in the sinusitis Visual Analogue Scale (VAS) score from baseline were measured at each evaluation time point. The total score is 0-10 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 32 weeks

  7. Immunogenicity: The incidence of drug-resistant antibodies (ADA) and their titers, and the incidence of neutralizing antibodies (Nab).

    Immunogenicity: The incidence of drug-resistant antibodies (ADA) and their titers, and the incidence of neutralizing antibodies (Nab) in subject. If the subject tests positive for ADA, neutralizing antibodies are added.

    Time frame: 0h (The first dose), D113, D169 and during withdrawal

  8. Changes in nasal polyp scores of subjects with chronic sinusitis with nasal polyps (CRSwNP) in part A

    Changes in nasal polyp scores of subjects with chronic sinusitis with nasal polyps (CRSwNP) at each evaluation time point were compared with baseline values (TQH2722-II-02 in the main study and baseline values in this study, respectively).

    Time frame: Weekends 0, 8, 16, 24 and 32

  9. Changes in Sino-nasal Outcome Test (SNOT-22) in part A

    Changes in Sino-nasal Outcome Test (SNOT-22) from baseline for subjects at each evaluation time point.

    Time frame: Weekends 0, 8, 16, 24 and 32

  10. Changes in nasal congestion score (NCS) in part A from baseline

    The changes in nasal congestion score (NCS) from baseline at each evaluation time point in Part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 32 weeks

  11. Changes in nasal/posterior runny nose scores in part A from baseline

    Changes in subjects' nasal/posterior runny nose scores from baseline at each evaluation time point. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 32 weeks

  12. Changes in the anosmia score in part A from baseline

    The changeS in the anosmia score from baseline at each evaluation time point in part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 32 weeks

  13. Changes of olfactory loss score in part B from baseline

    In Part B, the change of subjects' olfactory loss score from baseline (using the main study TQH2722-II-02 and the baseline value in this study, respectively) at each evaluation time point. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 32 weeks

  14. Changes in nasal endoscopic modified Lund-Kennedy scores in part B

    In Part B, changes in subjects' nasal endoscopic modified Lund-Kennedy scores from baseline (using the main study TQH2722-II-02 and the baseline in this study, respectively) at each evaluation time point are measured. The total score is 0-24 points, with the higher score meaning the more severe symptoms.

    Time frame: Weekends 0, 8, 16, 24 and 32

  15. Changes in Sino-nasal Outcome Test (SNOT-22) in part B

    In Part B, change from baseline in Sino-nasal Outcome Test (SNOT-22) for subjects at each evaluation time point.

    Time frame: Weekends 0, 8, 16, 24 and 32

07

Study locations

27 sites
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality 100730, China
  • The First People's Hospital of Foshan
    Foshan, Guangdong 528000, China
  • The Second People's Hospital of Shenzhen
    Shenzhen, Guangdong 518035, China
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi 530021, China
  • Hebei Medical University Third Hospital
    Shijiazhuang, Hebei 050000, China
  • Cangzhou Central Hospital
    Cangzhou, Heibei 061017, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • Union Hospital, Tongji Medical College, Huazhong University of science and technology
    Wuhan, Hubei 430022, China
  • Renmin Hospital of Wuhan University Hubei General Hospital
    Wuhan, Hubei 430060, China
  • Loudi Central Hospital
    Changsha, Hunan 417000, China
  • Baotou Central Hospital
    Baotou, Inner Mongolia 014000, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Jilin Provincial People's Hospital
    Changchun, Jilin 130021, China
  • The Affiliated Hospital of Yanbian University
    Yanji, Jilin 133002, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110002, China
  • Shengjing Hospital Affiliated to China Medical University
    Shenyang, Liaoning 110004, China
  • The Central Hospital of Shenyang Medical College
    Shenyang, Liaoning 110075, China
  • Shandong Second People's Hospital
    Jinan, Shandong 250299, China
  • Weihai Central Hospital
    Weihai, Shandong 264499, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
  • Zibo Central Hospital
    Zibo, Shandong 255036, China
  • Renji Hospital Shanghai Jiaotong University School of Medical
    Shanghai, Shanghai Municipality 200127, China
  • First Hospital of Shangxi Medical University
    Taiyuan, Shangxi 030001, China
  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610021, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830011, China
  • Taizhou central hospital(Taizhou university hospital)
    Taizhou, Zhejiang 318000, China
  • Wenling First People's Hospital
    Wenling, Zhejiang 317599, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Dec 2025, 17 months.

Of 16 phase 2 interventional studies under Rhinosinusitis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 3, 2024
StartActual
Jul 16, 2024
Primary completionActual
Dec 19, 2025
CompletionActual
Dec 19, 2025
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06439381
Responsible party
Sponsor
First posted
Jun 3, 2024
Start date
Jul 16, 2024
Primary completion
Dec 19, 2025
Completion
Dec 19, 2025
Last update
Aug 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion